Milne Jill C. 4

What Happened
Jill C. Milne, a non-employee director of BioCryst Pharmaceuticals (BCRX), received three grants on 2026-01-23: 2,582 shares issued in connection with BioCryst’s merger with Astria (conversion of 4,377 Astria shares), 12,272 restricted stock units (RSUs), and 26,684 stock options (a derivative grant). The merger-related exchange also included cash consideration of $8.55 per Astria share, which for Ms. Milne’s 4,377 Astria shares equals approximately $37,423.35 before taxes. These were awards/grants (not open-market purchases or sales).

Key Details

• Transaction date: 2026-01-23; Form 4 filed 2026-01-27 (filed within the typical 2-business-day window).
• Grants: 2,582 shares (merger conversion, footnote F1), 12,272 RSUs (footnote F2), 26,684 stock options (footnotes F3–F4). Total listed awards = 41,538 equity instruments.
• Cash from merger: Ms. Milne received ~$8.55 per Astria share converted (4,377 shares → ~ $37,423.35 before withholding).
• Vesting: RSUs vest in three equal annual installments starting 12 months after grant (F2). Options vest 1/36 per month over 3 years from grant (F4).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: No late filing flag noted.

Context

• The 2,582 shares were issued as part of the Astria merger consideration (partial stock + cash conversion), while the RSUs and options are routine automatic non-employee director compensation under BioCryst’s director policy.
• These are awards/grants (A); they do not represent an open-market purchase (bullish signal) or sale (liquidation). Grants reflect compensation and alignment with shareholders rather than an independent expression of trading sentiment.